Cardium Therapeutics, Inc. (Cardium) is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address unmet medical needs. With additional products and distribution channels, the Company plans to develop MedPodium into a portfolio of science-based, easy to use medicinals, neurologics, metabolics, nutraceuticals and aesthetics intended to promote and manage personal health. The lead product candidate from the Company�s Cardium Biologics unit is Generx (alferminogene tadenovec, Ad5FGF-4), which is developed as a treatment for myocardial ischemia due to coronary heart disease. Cardium�s Tissue Repair Company subsidiary is focused on the development of therapeutics and devices for the treatment of chronic wounds. On December 31, 2011, it acquires 15% ownership interest in SourceOne Global Partners, LLC. In October 2012, its MedPodium operating unit acquired the assets, business and product portfolio of To Go Brands.